Although we preliminarily investigated the possibility of CK/ALT for clinical application and determined the lower limit of normal (LLN) of CK/ALT in patients with dystrophinopathy, a further study based on patients' data is necessary before its application in the clinic. This evidence concerns the gene GPT and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.